The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of the pharmacokinetics (PK) of galeterone novel oral formulations.
William G. Kramer
Consultant or Advisory Role - Tokai
Bradley Vince
Research Funding - Tokai
Carolyn McGarry
Employment or Leadership Position - Tokai
Stock Ownership - Tokai